Navigation Links
Idenix Announces Data Presentations at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL)
Date:3/7/2011

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that two abstracts have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL, March 30- April 3, 2011 in Berlin, Germany).  Full abstracts can now be viewed at the EASL website at www.easl.eu.

The accepted abstracts are as follows:

  • Standring, et al, "Idenix NS5A HCV Replication Inhibitors with Low Picomolar, Pan-Genotypic in vitro Antiviral Activity" will be presented in a poster session beginning on Friday,  April 1.

  • Standring, et al, "No Resistance to IDX184 Was Detected in 3-day and 14-day Clinical Studies of IDX184 in Genotype 1-Infected HCV Subjects" will be presented in a poster session on Saturday, April 2.

  • About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. For further information about Idenix, please refer to www.idenix.com.

    Forward-looking Statements  This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the forego
    '/>"/>

    SOURCE Idenix Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    2. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
    3. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
    4. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
    5. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
    6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
    8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    9. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
    10. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
    11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/17/2014)... Mindray (NYSE: MR)announced its new generation DC-70 ... has been showcased for the first time at ISUOG ... and is scheduled for availability in the U.S. market ... most efficient workhorse in the mid-range segment, the DC-70 ... optimized user experience including a gesture-sensitive touch screen, delivering ...
    (Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... the following Product Segments: SPECT Systems (Includes SPECT and SPECT/CT ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... and forecasts are provided for the period 2013 through 2020. ...
    (Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
    Breaking Medicine Technology:Quality Exams at Your Fingertips 2Global Nuclear Medicine Imaging Equipment Industry 2Global Nuclear Medicine Imaging Equipment Industry 3Global Nuclear Medicine Imaging Equipment Industry 4Global Nuclear Medicine Imaging Equipment Industry 5Global Nuclear Medicine Imaging Equipment Industry 6Global Nuclear Medicine Imaging Equipment Industry 7Global Nuclear Medicine Imaging Equipment Industry 8Global Nuclear Medicine Imaging Equipment Industry 9Global Nuclear Medicine Imaging Equipment Industry 10Global Nuclear Medicine Imaging Equipment Industry 11Global Nuclear Medicine Imaging Equipment Industry 12Global Nuclear Medicine Imaging Equipment Industry 13Global Nuclear Medicine Imaging Equipment Industry 14Global Nuclear Medicine Imaging Equipment Industry 15Global Nuclear Medicine Imaging Equipment Industry 16Global Nuclear Medicine Imaging Equipment Industry 17Global Nuclear Medicine Imaging Equipment Industry 18Global Nuclear Medicine Imaging Equipment Industry 19Global Nuclear Medicine Imaging Equipment Industry 20Global Nuclear Medicine Imaging Equipment Industry 21Global Nuclear Medicine Imaging Equipment Industry 22Global Nuclear Medicine Imaging Equipment Industry 23Global Nuclear Medicine Imaging Equipment Industry 24Global Nuclear Medicine Imaging Equipment Industry 25Global Nuclear Medicine Imaging Equipment Industry 26Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4
    ... (Nasdaq: VPHM ) today announced that its ... cytomegalovirus (CMV) disease in liver transplant patients has been ... being moved to the current standard of care. The ... Phase 3 study of maribavir in stem cell transplant ...
    ... children for acute osteomyelitis--a bacterial bone infection--an early changeover ... just as effective as continuing the IV therapy, according ... more convenient for children and families, and avoid a ... from using central catheters, such as infections or breaks ...
    Cached Medicine Technology:ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 2ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 3ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients 4Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 2Early Switch from IV to Oral Meds Is Effective for Children with Acute Bone Infection 3
    (Date:9/17/2014)... Angeldress.co.uk is a popular ... occasion outfits for worldwide clients. According to Leo, the ... opening the first flagship retail store. Moreover, it is ... company has unveiled its new range of amazing wedding ... its new products are offered at greatly discounted prices, ...
    (Date:9/17/2014)... (PRWEB) September 17, 2014 There’s ... interruptions, giving girls of all ages an all-natural ... company founded by women, for women, announces the ... (http://GirlU.com) to relieve the symptoms commonly ... and irritability. , As a lifelong health ...
    (Date:9/17/2014)... San Diego, CA (PRWEB) September 17, 2014 ... Dermatology in San Diego, Dr. William Groff, an expert on ... of treating it. Pearly penile papules , or PPP, ... twenties and thirties, although other men may be affected as ... head of the penis. , “While PPP is not ...
    (Date:9/17/2014)... 17, 2014 A raucous childhood in ... together to form author Nancy Chovancek’s laughter-filled new book, ... a collection of short stories that prove the best ... With a positive message of empowerment and resilience, everyone ... a proven author with two books under her belt ...
    (Date:9/17/2014)... GA (PRWEB) September 17, 2014 ... District (DHCHD) has implemented its CollaborNet™ Health ... exchange of patients’ health information between Coon Memorial ... Texas, and physicians in the community. , ... application to enable electronic referrals by physicians to ...
    Breaking Medicine News(10 mins):Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 2Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 3Health News:Girl Uninterrupted® Debuts New Look for All-Natural, PMS-Relief Supplement, Launching Today 4Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 2Health News:Dallam-Hartley Counties Hospital District Deploys Holon's Health Information Exchange (HIE) Solution to Facilitate Improved Patient Care 3
    ... 2007 A review published in Dermatologic Therapy reveals that ... the same way as women but require higher doses of ... become a growing interest in cosmetic procedures by men. Although ... male patients who seek treatment is slowly increasing. , ...
    ... ceremony of, facility being built to serve the western Palm ... ... Dec. 28 The Health Care District,of Palm Beach County Board ... Board of Directors recently,dedicated the 50 acres of land on which ...
    ... plus fluticasone therapy led to better health, large trial ... People suffering with chronic obstructive pulmonary disease (COPD) may ... risk of death within two years as well and ... new research suggests. , The conclusion is drawn ...
    ... Dec. 28 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX,- ... for Drug Delivery,Platforms, announce that in order to ... directors, consultants and employees plan to,exercise stock options ... Lee, President and CEO, will cancel 6,000,000 options,granted ...
    ... NYSE Agrees to a Trading Extension of KV,s Securities until February ... ... 2008, ST. LOUIS, Dec. 28 KV Pharmaceutical Company,(NYSE: ... markets technology differentiated,branded and generic/non-branded prescription pharmaceutical products,announced today that NYSE ...
    ... of the Philadelphia Ronald McDonald House, will ... Ceremony on, Thursday, January 3rd; House ... PHILADELPHIA, Dec. 28 The 27,000-square-foot,three-story "Philadelphia Ronald ... its doors on Monday, January 7, 2008 - ...
    Cached Medicine News:Health News:Work Begins on New Regional Hospital Medical Campus 2Health News:Work Begins on New Regional Hospital Medical Campus 3Health News:Work Begins on New Regional Hospital Medical Campus 4Health News:Drug Combo Halves Death Risk for Severe COPD Patients 2Health News:AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:'Philadelphia Ronald McDonald House(R) at Front & Erie' Celebrates Grand Opening 2
    For the direct colorimetric determination of Urea Nitrogen (BUN) in human serum or plasma....
    ... Intended for the quantitative ... serum. Reaction: kinetic, lag phase ... followed by linear phase of ... 340 nm. Linearity: 120 mg/dL ...
    For the quantitative determination of Urea Nitrogen in serum. Linearity: 80 mg/dl. Reaction measured at 340 nm....
    For the quantitative determination of direct bilirubin in human serum. Linearity: 20 mg/dl...
    Medicine Products: